National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for metastatic triple negative breast cancer. HTA ID: 21059

Pembrolizumab in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) in adults whose tumours express PD-L1 with a combined positive score (CPS) ≥ 10 and who have not received prior chemotherapy for metastatic disease.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 29/11/2021
Rapid review completed 13/01/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with chemotherapy compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.